Dual-action teeth whitening and sensitivity relief with PVM/MA-calcium peroxide complex
Innovative dual-action technology that whitens teeth and reduces sensitivity using a moisture-activated PVM/MA-calcium peroxide complex in anhydrous formulations like toothpaste or gels.
Overview
This cutting-edge technology combines teeth whitening with sensitivity relief through a dual-action system using vinyl methyl ether-co-maleic anhydride (PVM/MA) polymers and calcium peroxide. When applied in a moisture-activated anhydrous formulation, such as toothpaste or gel strips, the technology effectively whitens teeth and forms a protective film to reduce sensitivity.
Technical specifications
Key features:
- Utilizes PVM/MA polymers known for their excellent oral mucoadhesive properties
- Moisture activation triggers hydrogen peroxide generation for effective teeth whitening
- PVM/MA-calcium film coats teeth, minimizing sensitivity by occluding dentin tubules
- Compatible with common dental care ingredients like silica and NaF, enhancing enamel protection
- Applicable in various delivery systems, including anhydrous toothpaste and gel strips
Technology readiness level
This technology is at TRL 3, indicating active research and experimental proof of concept. Further validation is required to transition into commercial applications.
About Boai NKY Medical Holdings Ltd.
Boai NKY Medical Holdings Ltd. (NKY Group) is a China-based, Shenzhen Stock Exchange-listed company (stock code: 300109) established in 2003, with roots tracing back to a 1987 state-owned chemical plant. The company operates through two primary business segments: fine chemicals and precision medicine. Its fine chemical division focuses on the research, development, and production of polyvinylpyrrolidone (PVP) and PVM/MA (Orarez) polymer series. NKY is recognized as the largest Chinese manufacturer of PVP and the third largest globally, utilizing advanced production facilities in Jiaozuo and Shanghai to produce materials used across the pharmaceutical, personal care, food and beverage, and new energy industries.
The company’s precision medicine segment includes the manufacturing of in vitro diagnostic products and investments in innovative oncology pharmaceuticals. NKY’s business model emphasizes technological innovation, international development, and rigorous quality standards, being the first Chinese manufacturer to achieve EXCiPACT GMP certification for its pharmaceutical excipients. With a global distribution network spanning over 50 countries, the company serves multinational partners by providing specialized polymer solutions and diagnostic tools. NKY is committed to sustainable development, evidenced by its membership in the United Nations Global Compact and ongoing efforts in environmental responsibility, including the conversion to green production processes and resource recycling.
delivered to your inbox.